Tenaya Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 12,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of $1.97 per share, which is equal to the closing price of Tenaya's common stock on November 15, 2024. Each stock option has a ten-year term and vests as follows over a total of four years: 1/4th of the original number of shares subject to the stock option shall vest on the one-year anniversary of the employee's date of hire and 1/48th of the original number of shares subject to the stock option shall vest every month thereafter, subject to such employee's continued service with Tenaya on each such date.
加利福尼亞州南舊金山，2024年11月19日（環球新聞通訊） -- Tenaya Therapeutics Inc.（納斯達克：TNYA）是一家臨床階段的生物技術公司，旨在發現、開發和提供可能治癒的療法，以解決心臟疾病的根本原因，今天宣佈已向兩名新非執行員工授予了購買總計12,000股Tenaya普通股的期權，以便於他們的入職。該期權的行使價格爲每股1.97美元，這與2024年11月15日Tenaya普通股的收盤價相等。每個期權的有效期爲十年，並按照如下方式在四年內逐步解鎖：在員工入職一週年之際，原始數量的四分之一的股份將解鎖，之後每個月將解鎖原始數量的1/48的股份，前提是該員工在每個解鎖日仍在Tenaya工作。
The stock options are subject to the terms and conditions of the Tenaya Therapeutics Inc. 2024 Inducement Equity Incentive Plan and related forms of agreements, and were granted as an inducement material to each new employee's acceptance of employment with Tenaya in accordance with NASDAQ Listing Rule 5635(c)(4).
該期權受Tenaya Therapeutics Inc. 2024年誘導性股權激勵計劃及相關協議形式的條款和條件的約束，並作爲每位新員工接受Tenaya工作的誘因，符合納斯達克上市規則5635(c)(4)。
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya's pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit .
關於Tenaya Therapeutics
Tenaya Therapeutics股份有限公司是一家臨床階段生物技術公司，致力於發現、開發和交付有可能治癒心臟疾病根本原因的療法。公司利用其集成且相互關聯的基因治療、細胞再生和精準醫療平台以及專有核心能力，推進了一系列新穎療法的管線，具有多種治療模式，以治療罕見的遺傳性心血管疾病和更常見的心臟病症。Tenaya研發的最先進的候選藥物包括：TN-201，一種用於MYBPC3相關肥厚型心肌病（HCM）的基因療法；TN-401，一種用於PKP2相關的室性心律失常性右心室心肌病（ARVC）的基因療法；以及TN-301，一種小分子HDAC6抑制劑，最初是爲保留射血分數的心衰（HFpEF）而開發的。Tenaya還有多個早期項目正在進行臨床前開發。欲了解更多信息，請訪問 。
Tenaya Therapeutics是一家臨床階段的生物技術公司，致力於一個大膽的使命：發現、開發和提供可能治癒的療法，以解決心臟疾病的根本驅動因素。Tenaya擁有一套綜合的內部能力，包括無特定模式的目標驗證、包膜工程和製造，以生成針對稀有遺傳疾病和更常見心臟疾病的基因藥物組合。Tenaya的產品管線包括TN-201，一種針對MYBPC3相關肥厚型心肌病（HCM）的基因療法；TN-401，一種針對PKP2相關心律失常右室心肌病（ARVC）的基因療法；TN-301，一種小分子HDAC6抑制劑，旨在治療保留射血分數的心力衰竭（HFpEF）；以及多個處於臨床前開發早期階段的項目。有關更多信息，請訪問。
CONTACT: Contact
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
聯繫人：聯繫
Michelle Corral
企業傳訊和投資者關係副總裁Michelle Corral：IR@tenayathera.com；Anne-Marie Fields：Annemarie.fields@precisionaq.com
IR@tenayathera.com
